GO:0010879 cholesterol transport involved in cholesterol storage

Cholesterol is an essential lipid that must be precisely distributed among cellular membranes, and its accumulation within cells is a regulated process. GO:0010879, cholesterol transport involved in cholesterol storage, captures the directed movement of cholesterol into cells that is part of its accumulation and maintenance. This biological process is fundamental to understanding how cells handle excess cholesterol and how defects in this trafficking lead to disease. The term is particularly relevant to lysosomal storage disorders, where cholesterol and other lipids accumulate to toxic levels. Researchers studying metabolic diseases, neurodegeneration, and lipid trafficking rely on this ontology term to annotate genes and pathways that control cholesterol storage. The most intensively studied context for GO:0010879 is the lysosome, where cholesterol derived from endocytosed lipoproteins must be exported to other cellular membranes. This export requires the coordinated action of NPC1 and NPC2, two proteins that bind and transfer cholesterol. When either protein is dysfunctional, cholesterol and glycolipids accumulate in lysosomes, leading to Niemann-Pick disease type C, a progressive neurodegenerative disorder. Beyond lysosomal storage diseases, hepatic cholesterol transport influences the development of non-alcoholic fatty liver disease and atherosclerosis, highlighting the broad physiological importance of this process. Understanding GO:0010879 at the molecular level provides a foundation for therapeutic development and for interpreting genomic data in metabolic and neurodegenerative disorders. The process is not merely a passive diffusion but an active, protein-mediated transport step that is subject to regulation and can be studied using modern CRISPR-based models. This article synthesizes authoritative QuickGO annotation data and verified PubMed literature to provide a research-grade overview of the genes, mechanisms, and experimental approaches relevant to cholesterol transport involved in cholesterol storage.

GO:0010879, cholesterol transport involved in cholesterol storage, is defined as the directed movement of cholesterol into cells that is part of its accumulation and maintenance. In practical terms, it describes the protein-mediated transfer of cholesterol molecules to specific cellular destinations where they are stored or used, rather than being degraded or excreted. This process is distinct from general cholesterol transport because it specifically contributes to the accumulation and maintenance of cholesterol pools within cells. The term is annotated to biological processes involving lysosomal cholesterol egress, intracellular trafficking, and membrane contact sites that facilitate cholesterol distribution.

GO:0010879 is important because dysregulation of cholesterol storage underlies some of the most severe inherited metabolic and neurodegenerative disorders. Niemann-Pick disease type C, caused by mutations in NPC1 or NPC2, is a fatal lysosomal lipid storage disorder in which cholesterol and glycolipids accumulate in the brain and liver, leading to progressive neurodegeneration and organ failure. The process also intersects with hepatic cholesterol transport, which is a key factor in non-alcoholic fatty liver disease and atherosclerosis. Understanding the molecular players and regulatory mechanisms of cholesterol storage is therefore essential for developing targeted therapies and for interpreting genetic variants in metabolic and neurological disease research.

The following genes and proteins are central to cholesterol transport involved in cholesterol storage, based on verified literature and their established roles in lysosomal cholesterol egress and related metabolic pathways.

Cholesterol transport involved in cholesterol storage is regulated at multiple levels, including transcriptional control by SREBP and LXR pathways, post-translational modification of transport proteins, and feedback sensing of lysosomal cholesterol levels. In lysosomal storage diseases, impaired cholesterol egress triggers compensatory changes in cholesterol synthesis and uptake, which can further exacerbate lipid accumulation. Additionally, cholesterol accumulation has been linked to regulated pyroptosis, suggesting crosstalk between lipid storage and inflammatory cell death pathways. The process is also influenced by membrane contact sites and lipid transfer proteins such as STARD3 and OSBP, which facilitate cholesterol distribution between organelles.

Niemann-Pick disease type C is an autosomal recessive lysosomal storage disorder caused by mutations in NPC1 or NPC2, leading to impaired cholesterol egress from lysosomes. The disease is characterized by progressive neurodegeneration, hepatosplenomegaly, and accumulation of unesterified cholesterol and glycolipids in various tissues. The transport defect directly corresponds to GO:0010879, as cholesterol accumulates in lysosomes instead of being distributed to other cellular membranes. Research using CRISPR knockout and point-mutation models of NPC1 has provided insights into the molecular basis of the disease and potential therapeutic targets.

Hepatic cholesterol transport plays a central role in the pathogenesis of non-alcoholic fatty liver disease and atherosclerosis. Dysregulation of cholesterol uptake, storage, and efflux in hepatocytes and macrophages contributes to lipid accumulation, inflammation, and plaque formation. Genes such as ABCA1, ABCG1, and SOAT1 are critical for maintaining cholesterol homeostasis, and their dysfunction promotes disease progression. Studying these genes in CRISPR models can help identify causal mechanisms and potential therapeutic interventions.

Beyond Niemann-Pick disease type C, several lysosomal lipid storage diseases involve impaired cholesterol trafficking and storage. These include lysosomal acid lipase deficiency, which leads to cholesteryl ester accumulation, and other rare disorders affecting lipid catabolism. Common themes include lysosomal dysfunction, membrane trafficking defects, and secondary accumulation of cholesterol and glycolipids. Understanding the shared mechanisms of these diseases provides a broader context for GO:0010879 and its role in cellular pathology.

Recent evidence links cholesterol accumulation to regulated pyroptosis, a form of inflammatory cell death. Lipid rafts and cholesterol-rich membrane domains are involved in signaling pathways that activate inflammasomes and gasdermin pores. This connection suggests that dysregulated cholesterol storage may contribute to inflammatory diseases and that targeting cholesterol transport could modulate pyroptosis in disease contexts. Further research using CRISPR models is needed to dissect these interactions.

Filipin is a polyene antibiotic that binds specifically to unesterified cholesterol and is widely used to visualize cholesterol accumulation in cells. In cells with defective cholesterol transport, filipin staining reveals punctate lysosomal accumulation, which is a hallmark of Niemann-Pick disease type C. This method is essential for validating CRISPR knockout and point-mutation models of genes involved in GO:0010879.

Mass spectrometry-based lipidomics allows comprehensive quantification of cholesterol and cholesteryl esters in cells and tissues. This approach can measure the impact of genetic perturbations on cholesterol storage and identify secondary lipid changes. Lipidomic profiling is particularly useful for studying hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis.

Proteomic approaches can identify protein-protein interactions and post-translational modifications that regulate cholesterol transport. For example, affinity purification mass spectrometry has been used to study NPC1 and NPC2 interactions. These methods help build a systems-level understanding of the molecular machinery involved in cholesterol storage.

RNA sequencing and CRISPR-based genetic screens can uncover genes and pathways that regulate cholesterol storage. Genome-wide knockout screens with filipin-based sorting can identify novel regulators of lysosomal cholesterol egress. These functional genomics approaches are powerful for discovering new therapeutic targets and annotating the GO:0010879 pathway.

Researchers studying cholesterol transport involved in cholesterol storage-related genes often need to determine whether a candidate gene is causally involved in lysosomal cholesterol egress, intracellular distribution, or storage regulation. Establishing causality requires precise genetic models that can knockout, mutate, tag, or overexpress the gene of interest in relevant cell types. EDITGENE provides a comprehensive suite of CRISPR services tailored to these needs, enabling rigorous investigation of GO:0010879 and its associated pathologies.

GO:0010879, cholesterol transport involved in cholesterol storage, is a fundamental biological process that governs how cells accumulate and maintain cholesterol. Its most well-characterized mechanism involves NPC1 and NPC2 in lysosomal cholesterol egress, and defects in this pathway cause severe diseases such as Niemann-Pick disease type C. Beyond lysosomal storage disorders, cholesterol storage is implicated in hepatic steatosis, atherosclerosis, and inflammatory cell death, making it a broad research area. Advances in CRISPR-based genetic models and lipidomics are accelerating our understanding of the genes and regulatory networks that control cholesterol transport. Researchers can now precisely knockout, mutate, or overexpress candidate genes to establish causality and identify therapeutic targets. EDITGENE provides end-to-end support for such studies, from custom cell model generation to bioinformatics analysis, empowering discoveries in metabolic and neurodegenerative disease research.